Scandion Oncology Q1 2024: No surprises - Redeye - Börskollen
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Scandion Oncology Q1 2024: No surprises - Redeye

{newsItem.title}

Redeye provides its initial take on Scandion Oncology's Q1 2024 report. The company's first-quarter burn rate broadly aligned with our expectations and we understand that it is well on its way to run CORIST part 3 expansion cohorts. We will await the final terms of the company's recently announced rights issue to adjust our estimates and valuation. Thus, we will revert with our quarterly update after Scandion publishes final terms in the coming days.

Länk till analysen i sin helhet: https://www.redeye.se/research/1009877/scandion-oncology-q1-2024-no-surprises?utm_source=finwire&utm_medium=RSS

Nyheter om Scandion Oncology

Läses av andra just nu

Om aktien Scandion Oncology

Senaste nytt